Latest News & Features
Americas
In an interview with LSIPR, Hans Sauer, deputy general counsel for intellectual property at the Biotechnology Innovation Organization, explains more about the big issues affecting it at the moment and how the trade association is responding. 6 June 2016
Biotechnology
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR. 5 June 2016
Biotechnology
The biotech industry on both sides of the Atlantic is facing serious challenges in protecting its inventions, argues Nathalie Moll, secretary general of EuropaBio, which is organising a discussion on the topic at the 2016 BIO International Convention in San Francisco. 5 June 2016
Americas
Mexico and other signatories to the TPP face a number of challenges on the IP front in implementing its reforms, as Iliana Ramirez Villaseñor of Leyva, Montenegro, Trigueros Abogados reports. 3 June 2016
Europe
In Russia, more attention is being paid towards the correlation between IP rights and competition restrictions, and pharma companies should keep abreast of developments, says Ilya Goryachev of Gorodissky & Partners. 3 June 2016
Americas
A pending case at the US Court of Appeals for the Federal Circuit may give the pharmaceutical and biotechnology industry important guidance on issues surrounding third-party contract manufacturing and the on-sale bar to patentability, as Porter Fleming and Jason Kanter of Frommer Lawrence & Haug report. 2 June 2016
Big Pharma
With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe. 2 June 2016
article
Minesoft’s Chemical Explorer helps users to find chemical information in patents issued by multiple authorities. Robert Poolman explains how it works. 2 June 2016
Americas
Pay-for-delay agreements, otherwise known as reverse settlements, stand at the intersection of intellectual property and competition law, but the clarity hoped for after Actavis has not yet arrived. LSIPR investigates. 1 June 2016
Big Pharma
Despite several major EU rulings on supplementary protection certificates, national IP offices and courts can form differing interpretations, and it seems that a unitary-style SPC right would be hard to create. LSIPR reports. 1 June 2016